<SEC-DOCUMENT>0001104659-20-004124.txt : 20200115
<SEC-HEADER>0001104659-20-004124.hdr.sgml : 20200115
<ACCEPTANCE-DATETIME>20200115060413
ACCESSION NUMBER:		0001104659-20-004124
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200114
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200115
DATE AS OF CHANGE:		20200115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		20527250

	BUSINESS ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		2489609009

	MAIL ADDRESS:	
		STREET 1:		411 HACKENSACK AVE., SUITE 501
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm203460-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<B>January 14, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ROCKWELL MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-23661</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>38-3317208</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other<BR>
jurisdiction of<BR>
incorporation)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File<BR>
Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>411 Hackensack Avenue, Suite 501, Hackensack,
New Jersey 07601</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(248) 960-9009</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&nbsp;12(b)&nbsp;of
the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title&nbsp;of&nbsp;Each&nbsp;Class</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading&nbsp;Symbol</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name&nbsp;of&nbsp;Each&nbsp;exchange&nbsp;on&nbsp;which<BR>
registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, par value $0.0001</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">RMTI</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Nasdaq Global Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule&nbsp;12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act.&nbsp;&nbsp; <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in; text-align: left"><B><U>Item 8.01</U></B></TD><TD STYLE="text-align: justify"><B><U>Other Events</U>.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 14, 2020, Rockwell Medical,&nbsp;Inc.
(the &ldquo;Company&rdquo;) issued a press release announcing that the Company has entered into license and supply agreements with
a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. for the rights to commercialize Triferic (ferric pyrophosphate
citrate) in India. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in; text-align: left"><B><U>Item 9.01</U></B></TD><TD STYLE="text-align: justify"><B><U>Financial Statements and Exhibits</U>.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left">(d)</TD><TD STYLE="text-align: justify; width: 0.25in">&nbsp;&nbsp;<I>Exhibits</I>.</TD>
                                                    <TD STYLE="text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following exhibit is being furnished herewith:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><A HREF="tm203460d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="tm203460d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release, dated January 14, 2020</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ROCKWELL MEDICAL,&nbsp;INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: January 15, 2020</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stuart Paul</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Stuart Paul</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm203460d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm203460d1_ex99-1img002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FOR IMMEDIATE RELEASE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Rockwell
Medical, Inc. Enters into Exclusive License and Supply <BR>
Agreements with Sun Pharma for the Rights to Commercialize <BR>
Triferic&reg; in India</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">- Sizable and growing market opportunity
with 120,000+ patients receiving hemodialysis annually &ndash;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>WIXOM, Mich., </B>January 14, 2020 &ndash; Rockwell Medical,
Inc. (NASDAQ:RMTI) (&ldquo;Rockwell Medical&rdquo; or the &ldquo;Company&rdquo;), a biopharmaceutical company dedicated to transforming
anemia management and improving outcomes for patients around the world, today announced that it has entered into license and supply
agreements with a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (together, &ldquo;Sun Pharma&rdquo;), for the rights
to commercialize Triferic (ferric pyrophosphate citrate) in India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the agreements, Sun Pharma will be the exclusive
development and commercialization partner for Triferic in India and Rockwell Medical will supply the product to Sun Pharma. In
consideration for the license, Rockwell Medical will receive an upfront fee, and will be eligible for milestone payments and royalties
on net sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sun Pharma is the largest pharmaceutical company in India, with
more than $4 billion in annual sales globally. Sun Pharma will leverage its market leading nephrology franchise to promote Triferic
to nephrologists in India. A Joint Alliance Committee, comprised of members from Rockwell Medical and Sun Pharma, will guide the
development and execution for Triferic in India. Sun Pharma will be responsible for all clinical, regulatory and commercialization
activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased to establish this important relationship
with Sun Pharma, which has a strong presence in the nephrology segment in India. With a dedicated business unit, market leading
sales force and medical support personnel, together with its experience with license and distribution partnerships with large global
pharmaceutical companies, Sun Pharma is well positioned to ensure that hemodialysis patients have access to our innovative therapeutic.
This is a meaningful advancement for Triferic as we expand our global footprint and drive the long-term value of Triferic,&rdquo;
said Stuart Paul, President and Chief Executive Officer of Rockwell Medical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Rockwell Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Rockwell Medical is a biopharmaceutical
company dedicated to transforming anemia management in a wide variety of therapeutic areas and across the globe, improving the
lives of very sick patients. The Company&rsquo;s initial focus is the treatment of anemia in end-stage renal disease (ESRD). Rockwell
Medical's exclusive renal drug therapy, Triferic (ferric pyrophosphate citrate), is the only FDA-approved therapeutic indicated
for iron replacement and maintenance of hemoglobin in hemodialysis patients. The Company has developed multiple formulations of
Triferic (1) FDA-approved Dialysate Triferic, and (2) I.V. Triferic, for which the Company filed a New Drug Application in May
2019. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates
to dialysis providers and distributors in the U.S. and abroad. Please visit www.rockwellmed.com for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sun Pharma is the world's fourth largest specialty generic pharmaceutical
company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality
products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is
supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural
workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&amp;D capabilities
across multiple R&amp;D centers, with investments of approximately 7% of annual revenues in R&amp;D. For further information, please
visit www.sunpharma.com &amp; follow us on Twitter @SunPharma_Live</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Triferic </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Triferic is the only FDA-approved therapy in the U.S. indicated
to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. Triferic has a unique
and differentiated mechanism of action which has the potential to benefit patients and health care economics. Triferic represents
a potential innovative medical advancement in hemodialysis patient iron management&ndash; with the potential to become the future
standard of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Triferic delivers approximately 5-7 mg iron with every hemodialysis
treatment to the bone marrow and maintains hemoglobin without increasing iron stores (ferritin). Triferic donates iron immediately
and completely to transferrin (carrier of iron in the body) upon entry into the blood and is then transported directly to the bone
marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no reports of anaphylaxis
in over 1,000,000 patient administrations, addressing a significant medical need in overcoming Functional Iron Deficiency (FID)
in ESRD patients. Please visit www.triferic.com to view the Triferic mechanism-of-action (MOA) video and for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important Safety Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Serious hypersensitivity reactions, including anaphylactic-type
reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products.
Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for
signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be
immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in
1 (0.3%) of 292 patients receiving Triferic in two randomized clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Iron status should be determined on pre-dialysis blood samples.
Post dialysis serum iron parameters may overestimate serum iron and transferrin saturation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The most common adverse reactions (&ge;3% and at least 1% greater
than placebo) in controlled clinical studies include: procedural hypotension (21.6%), muscle spasms (9.6%), headache (9.2%), pain
in extremity (6.8%), peripheral edema (6.8%), dyspnea (5.8%), back pain (4.5%), pyrexia (4.5%), urinary tract infection (4.5%),
asthenia (4.1%), fatigue (3.8%), arteriovenous (AV) fistula thrombosis (3.4%), and AV fistula site hemorrhage (3.4%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information, including full prescribing information,
visit: http://www.triferic.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Certain statements in this
press release may constitute &quot;forward-looking statements&quot; within the meaning of the federal securities laws, including,
but not limited to, Rockwell Medical&rsquo;s intention to bring to market Triferic, and I.V. Triferic. Words such as &quot;may,&quot;
 &quot;might,&quot; &quot;will,&quot; &quot;should,&quot; &quot;believe,&quot; &quot;expect,&quot; &quot;anticipate,&quot; &quot;estimate,&quot;
 &quot;continue,&quot; &quot;could,&quot; &quot;plan,&quot; &quot;potential,&quot; &quot;predict,&quot; &quot;forecast,&quot; &quot;project,&quot;
 &quot;intend&quot; or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking
statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed
on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking
statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without
limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual
results could be materially different. Risks and uncertainties include: statements about the issuance of a unique J code for our
Triferic Powder Packet; timing and regulatory approval process for Dialysate Triferic in China; the potential market opportunity
and commercialization of Dialysate Triferic in China upon regulatory approval; timing and regulatory approval process of our NDA
filing for I.V. Triferic as filed with the FDA; potential market opportunity for I.V. Triferic, as well as other Rockwell Medical
products; CMS&rsquo; announced final rule relating to eligibility criteria for TDAPA; liquidity and capital resources; expected
duration of Rockwell Medical&rsquo;s existing working capital; the success of our commercialization of Dialysate Triferic, which
commenced in May 2019; and timing and success of our efforts to maintain, grow and improve the profit margin of the Company&rsquo;s
concentrate business. Rockwell Medical expressly disclaims any obligation to update or alter any statements whether as a result
of new information, future events or otherwise, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Triferic<SUP>&reg;</SUP> is a registered trademark of Rockwell
Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations:<BR>
Lisa M. Wilson, In-Site Communications, Inc.<BR>
T: 212-452-2793<BR>
E: <U>lwilson@insitecony.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Source: Rockwell Medical, Inc</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm203460d1_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm203460d1_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X 04# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BO-=?\
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M&;_P;]?\% = _P""??[;6N_!7]HS1],\%?#S]H?4?^%1>,O$OB/2M,T[QG\
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M"_:TUR3XP:E)=HKZK:^ &0Z-\+](O+MX1/+YGAFV'B/8TTD)?Q!YJ(CLY/\
MGX?L3?L\ZA^VO^UI^SC^RUI8N-*N?CE\5M&\,>-IH[1%U7PGX)L3<>(OC+=3
M1$[A=>%O!.D>+K/3S,(?-UQM+@N)(6E!K_8)\(^&M!\&>'="\(>%],L]$\,>
M$=%TCPSX8T2QA,%KHWA_0=/M-)T;2[:-Y'(AL-/LH;>W.1_H\<1_A)K\Z\7U
ME7#V2X3@S(:M6.$SS,\RXRS2G0KJ$8/,L12IX#"+D3_W6BE4<TU&?-R^RBTV
M?2\'_7LUQ^(SK-*$Z/\ 9V%EEE"$Y<_M98=?5JF(C[L5"-1TVU!QEHVU)WYI
M?Y,_Q7^-^I?LT?\ !5;]H?\ :'TGP=X'\>ZG\'OVY_VF?%5CX)^(T-Y+X#\2
MRR?$KQWI::?XJ73'M]273X!?G5+>.VN%1[O3K>9T+0(1^FEQ_P '0GQK N'_
M .&!O^":COFZF42^#_& E<*SL Q75SO9C_RTRGFCYRD98JGYL>/?C=X?_9R_
MX*T?'KX\>(OAQX?^-VA_"7]O/]I/Q1K'P?\ $6HV&DZ1\0($^)?Q T8>&=1U
M/4],\3:=#$SZN=2/VCPY>+$]D%ECER GZTO_ ,'&_P"S,'=!_P $0OV2'2-Y
M8E<?%KP?.'$4C1%_,@_9@> ^9L+D)(X7)0L65C7Z;GV75L;2R>I5X(S+B>NL
MLP*I9GA,RJ8"C-0P>#IQG[&6<)3YE37OTZ>'7N-<D6]?ELES%X3$9JJV?RRZ
MG3QM=4Z4\GABN6'/>,?:ODE))2;ZK5OF;NE_:A_P3[\3>#OCK^R+^RS^U9_P
MJ'X2_#CXD?'7]GCX:_%'Q#'\-_!NEZ%IVC:G\0?">DZ[K6AZ%=B*;6UT&*\O
MGM;6&_U.\NI;."V%[/<W"R3/_ ?_ ,%?WD_XB%OB[R0%_:O_ &*%1LG[K?#;
M]GG>H_[Y'? (7N./WD_X)U_\'*MU^U%^U-^S3^Q1X>_8*\!_!/P;\1M2D\!:
M/K'AG]H>/7=/\!:/X>\&ZAKNGVNA^ X?@9X'M?[.M;/2HK"QTZUU-+>WB3RH
MIFV>8?YX?^"X'B^/P+_P77_:L\;I;6NKW/P^^,/[+GCN+0Y]272TU>Y\'_ K
MX(>)(M)FU!8+N33(]3DTQ+*74%LKM[..8W*VMR8_)?\ .?#[A[B'*N,\]P6;
M4)83%YEP;FTL-1Q&9TZCI4JV)QL:-.4I3K?#&M2HN'M+Q=.6CO>7TO$N9Y5B
MLGR_&8:<:N%PV?83'5*]/!5%%\DJ2G&2BHM3<HSE.HTXIVT=M?\ 4B48:/ Q
MB.W QQ@-Y@8<= 0B ^H50>@K\@?^"_IQ_P $?_VXCZ?"J!C^'BKP^?PZ8SVS
M7\Y$G_!XI\3A(0/^"?7PX>$*[@O^U9K322)!,MKA57X#NQ*F-Y&!1BR*7 /)
M;W[XH?\ !6'Q/_P5A_X(>_\ !5_Q_P"*O@AX7^!DWP8L_#?P^M]-\/?$V^^(
M]IKL.K0^'?%+ZU/J5UX7\(KIDD9NHX((#ID[?*QE?>JK'\7A/#WC'A_-L@S/
M,\LP]'"KB#+:%&=/,,-B)UJCQ=/EC"G!J[DXM)<W*^LDDV?0RXCRC,L'CZ>$
MKSK26%K/DC2FI-./*EM=.\E>RDTD]-4<O_P9X8^S?\%#"JX+:E^S,K$ Y?R]
M#^+(C!XY""1@O9 S8QN:O[8H?ON>,&.'Z]9?Z8Q7^5__ ,$FO^"QWB3_ ()-
M0?'N+PI^S]X4^/'_  OJ[^'<M[/XD^+$_P ,)O"Y^&5CXFLDMHX[#P?XV_MU
M=3_X2]IEU!K;3PIM'C\UVS%7[$I_P>%_%*26Q0_\$_OAI']KU"PL6>+]J;Q%
M<O'%>7EO;22QVZ? V.&X:(2APL][9#/R(\AD<)]?XC^'O&F><:\09G@,CG4P
M>(IX7,(XFKB,+0P\(+"485(3JNK)*4'&:6C<FEHN96\+A/B#)L)DV5Y?+$SC
MBZ=&I@XT*M*I&=24:TJKGS2344H)OE;;;5D]4S^[^BN8\*:S)KOAO0==EM8[
M&76M$T?5I+5)Q=10/J6FVMZT$5SB-KB.!IS LSP6[2B,/Y2JRT5_/E7$1H5:
ME&LX1JTI2A4C&:DE*+<6E+W;JZ>ME?YH_0X24X1G%.TDFM.Z/D_]K?X:^,]7
MT#1?C)\,].^)>O\ Q+^ FH:K\1/#7PI^%WBOPWX%N?V@[[3]+U&/2/A!XS\2
M>*+!K6/P=JE]<66HW2-JMM:B_@8LK%%BK\^?C]\";K]K?QGX>_:M_8T^(OA;
MX3_M[?L_1Z!X-^+?@R/Q+H?BO1]*\1S:#:ZWKW[/WQ=U/PY+J.EP>+?#3ZM=
MZ'+K4EOJWAR]BT^6SU.(P-9M:?N[7Q_\1/V5_#7BG6O"OC/P9J.N_"[Q?X4^
M)$OQ;O4^'=U'X2T'XI^-;?PW>:'I$7QE@TR""[\;^&[9IX9+VSN76[O5@^>8
M,=U?8\.\3YADN)P4L%CJF!QU&&/P<,?5P6&S/+L5DN9T/JV8\/9[EN.KQP>*
MR?%1E&JD\-B:\*\%5BZ4:,5/X/BWA/ YQ1Q2Q.!I8_ 8CZIC*N!I8O%99F6%
MSK+,3'%9?G^19CE]">,PV;T7[2C*2K8:C.E.,)2J.<TOS=TW_@I'^W#\,[&/
MPE^T7_P2[^/WB'X@V/G6 \3? 1K'Q7\.O%-[;RF.TOK,R--+HJ7<30A_L>N^
M)HTVL1;Z>\B6J>^V7A_XW_MJ>$]"\3_M*>&4_9K_ &==0\!Z!XJ\0_!K4/$G
MB[P)^T?X#^.GPS^+>KWL.J:_X\TF73?# ^$7B#P3H.@:O'I;30:E*MZ\.I(U
MM.YKYZM?AM_P7>^'@?1-)^,?[,?Q5TB)Y!9^)_$FG/HVL?8P]SY4%_:2:#$Z
M_9TDA6TDCO-0=HH<W!\UW#9-W_P3C_;Q_:OFBMOV[_VQEA^&TK))J'P;_9_L
MKW2]'UVV,HE;2_$&L7]IHNGW%N753(ITS504P(IDD4/7ZCC,KX)P]3"9M0XC
M\)^"*U3$/%XG%<-9GQSQIQ).A5IM2PF X7KY72P>54O;2G]6E/,'AL#5Y*=.
MI.C1M+\MP6:\<UUB<JJ\.>*7&<,'ET<-A:/$F6\&<%Y"\33KQ5+'8GB/#YK6
MQ>.Q$:=.DZW+@76Q=I8FI3C6K,\H_:(^)&H_\%</VE/!_P"R9^S]>W>J_LD_
M!+Q7I'C?]I#XJV0G?2/&5[83.NBZ?X=NPMQ!K_A^ZM8)['P\!)Y?B.>\NO$M
MD\UGH#7%?T4Z/HUKH&DZ;I&F:<;33])T^ST[3;*-"8-/L[*V2SM[2VCBC1_+
MMX[>,IO"[A.^QMJE5\K_ &>_V>?A-^S/X/L?AI\&?!^E^#_">GVGF74=M%#)
MK.OZR[0I=:_XEU=@VHZYK%VL2B6^U"5V1-EO;I!;Q1Q#Z"K\SXKXCPF<4,DR
M'):&(P?"W#& Q>7X.CB?JRQF=9AC*\JV9<49B\)7KT\+CLSFZ<:6 H5:E/ 8
M'#87"2G*=*<I_JO"7#..RZOG7$>=XVABN*N)JU.KC*V%IU'A<ERRC3HPP'#&
M7RQ5*A4Q."RJ,*D'C*M&G/&5ZU6NDX<C/A'P%_P3=_8;^&GQ:LOCSX%_99^%
M'A'XQ:;K^O\ B;3?B-H_AB&V\4VGB#Q3!>Q^(=6BOTFNI%N=:34]12^F8!G%
MP4=26W+]MQQ.%0>3M\LLNV(DF(["J%&GAMTFB$3!2!'\I^3,GS$:=%?*UZU?
M%.A]9KUL0L-3A2H*M4G4=.G3C&$(1E.4I*,8Q225DNB6Q]S&,8<[IQA3=1\U
M1PA&*G.R3FXI**<FG)VTNV?GE\3?^"6O_!/GXQ>./%GQ(^)7['GP4\9^.?&U
MW-J'BWQ-K7@NQ?6?$FISI;QM?:A?121J9FDM+6]DNUQ=BZM;>96\Y%#_ 'EI
M6DVF@:1IFAZ/;?8M,T;3K'2],M0TDZVUAIEK'96-NK2L\N(;:"*/=([RL!N=
MG?<6VZ*=?$XS%PC#%XROB?914*$JLY2E1I12C3I4[SG:%."C"*NO=BE9+111
MH8?#N3H4*=)3E*=2,(I*I4DVY3DK?%*3E)[ZR?9'YK?&C_@DK_P3C_:'UE_$
M_P 5_P!C'X):_P");BX:XO=<MO"T7AG4KNXG 2YFO+SPY#IDVH3O@L)[F ;A
M\QE0\CL?@/\ \$R?V"OV8=5M?$'P(_9.^#?@'Q)97"W%KXIM/"5CJ7B:TE$;
MQ&>RUO6X=9U*VF2*64));3VT@SM1MS;J^^**ZIYOG,Z7U=YQF/U1:+"O%5I4
M;.]TU*L[Q=VG%W33:M;0R> RYU/:K 86,E\/+2A[KTLX^[HTTFFDFFEUU,R&
M,A@QCD*NO=<D$?*))7>.*X>61=N_S%;:4VJ1U;DOB)\-O ?Q5\+WO@SXE>!_
M#'Q%\):IM74?"WC/P_I'B;0+O:,1RW>E:W%+9S-"3F-U4SH3F-@V:] HKSX<
M]/WHU:D:SDI?6(2<*R<7>/+*#3CRK1<K5E?NSHY='&7+.FU;V<X0E"W:TD[J
M^NJ>NN^I^3=W_P $/?\ @E'J/B"?Q+=?L,_!*34[FXDO+H)H6H6FFS7CRAY2
M-'BU&.R^SR,,B!E^S1HJI#$49C7WI\(_@!\&O@%HLGASX(_"/X=?";0G$$<F
MF^ /"6D>%X;A;>,1VWVT:-I5M/J:Q#G_ $R[FV_-AU)+5[A17=BLSS/'4XT<
M;F688JE&*@H5<9B91Y%;W>5UFG'1:-/5)[I-9TL-AZ+<X8;#1J7;52.'I0FK
M[I.,%HUH]5=>3L?-/[0G[)O[.W[5^B^'_#G[2/P9\#_&30_"FMS>(/#NF^-M
M(75K71=9NM.ETN]U73XG \BZN=/D>U+>=)F%PK>6X91U'P6^!/PE_9S^'ND_
M"?X&_#KP_P###X;Z#=ZG?:-X)\(Z<=+T/39]9U2[UO5Y[6V4M%'+J6JW\]U<
MJLC?,S'S)-N1[=17,L3C5AX8&.,K++(R<_[-;<\,ZKBX^UM*H^6I9OWU!R:;
M3E9LN4(RDZD8PIU[6C7A3A[2*TNDW'5-*S4FU9[7/E/]HC]E3]FK]J#P]H&C
M?M+?!SX<_&#1_!VK7/B#PW;_ !$\/V6KVNA:I<VTHUB^T^:Y-HVERZC:Q*-9
MA6[.GR06<,MS#*$ 7-_9T_9!_9;_ &4X?$-S^S%\'_ 'PDT_X@MIEUXJB^'M
MNVF:3XAETL2FPU>>TM#=VVI:@J2"Q-^!;R"Q4XF41I$Z_MX226_[$G[7-Q"S
MI]F_9M^,L\;*\D3P^1\/?$<RO$Z%91+NP68,B%  ).&-?RY?L?\ [9?[0O\
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M#X9^ UK\,7U+XG?%JWF\2Q7_ (PN[+3]3O?$PTV/36M;**\O8H=,5[XV5K)
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M&+;3CS-6UDHN44_Y92BTTVA.,9?%%/U5^WZI/Y(I?!G]E_X<? KQY^T/\1/
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EI?:OJ+1Q2W^IW"0J]Y>S*9KJ<O/(2SFBBBL6W)MO=N[]66?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
